Abstracts
OBJECTIVES:
The prevalence of Neisseria gonnorrhoeae (GC) among adolescents and young women attending urban emergency rooms (ER) ranges from 3% to 10% but screening has historically not been feasible in this setting. Our objective was to assess the cost-effectiveness of newer technologies that bypass the need for a pelvic exam and reduce loss to follow-up. METHODS: We developed a state-transition Markov model of the natural history of GC and simulated screening, diagnosis, and treatment in a cohort of 10,000 15year-old U.S. women. Adopting a societal perspective, we compared no screening to selective age-based screening using either the: 1) ligase chain reaction (LCR) on a urine sample; or 2) rapid immunochromotographic assay (RIA) on a clinician-collected vaginal sample. We assumed 80% of LCR screen-positive women would be treated (20% loss to follow-up) and 100% of RIA screen-positive women would receive immediate treatment. We assumed a peak GC prevalence of 6%. Clinical outcomes included cases of GC, pelvic inflammatory disease (PID), major PID sequelae, and quality-adjusted life expectancy (QALE). Economic outcomes included incremental costeffectiveness ratios (cost per quality-adjusted life year saved). Data were obtained from population-based studies, national databases and published literature. RESULTS: Compared to no screening, screening women aged 15 to 24 with RIA was more effective and costeffective (i.e., dominated) than LCR and cost $1,850 per QALY. Provided the RIA assay (base case $20) was less than $100, the cost-effectiveness ratio for screening with the rapid test was less than $10,000 per QALY. Results were stable despite varying the prevalence of GC, direct medical costs, and quality of life weights over a wide plausible range. CONCLUSIONS: Screening for GC within an urban-ER setting using the new RIA test facilitates rapid screening and treatment and has a cost-effectiveness ratio that is more attractive than many current preventive health interventions.
IN4

THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES
Becker R, Zaccagnini P, Rattana S Ovation Research Group, Highland Park, IL, USA OBJECTIVE: Brazil's universal access to HIV treatment and drug price reductions have affordably treated large segments of the country's HIV-infected population. Several countries in Central America have large HIVinfected populations without access to care. This analysis examines the feasibility of applying Brazil's universal access to treatment and drug price reductions given the economic conditions in three Central American countries: Guatamala (n = 71,050), El Salvador (n = 19,400), and Belize (n = 2,400). METHODS: Each country's HIV population not currently receiving antiretroviral therapy was estimated. For each population, the cost of two-drug and three-drug combination antiretroviral therapy was estimated by applying 2000 Brazilian prices (in U.S. dollars). The ratio of drug costs to gross domestic product was determined to measure each country's relative ability to pay for the cost of treatment. The Brazilian rate of cost savings from averted hospitalizations was subtracted from each country's drug cost estimates to determine total cost of treatment. RESULTS: In Guatamala, the drug costs for treating the HIV population ranges between $54.2 (0.117% of GDP) and $335.1 (0.725%) million depending on whether double or triple combination therapy is used. The costs range between $14.8 (0.062%) and $91.5 (0.381%) million in El Salvador, and between $1.8 (0.232%) and $11.3 (1.433%) in Belize. Potential hospitalization costs averted were $80.5 million in Guatamala, $22.0 million in El Salvador, and $2.7 million in Belize. Given these costs averted, the total cost of treatment ranges between -$28.5 (cost savings) and $252.4 million in Guatamala depending on whether double or triple combination therapy is used, between -$7.9 and $68.8 million in El Salvador, and between -$888.8 thousand and $8.6 million in Belize. CONCLUSIONS: Since the ratio of antiretroviral drug costs to GDP was 0.041% in Brazil in 2000, these three Central American countries may have more difficulty affording antiretroviral therapy unless double combination therapy is used. 
SESSION
OBJECTIVE:
An issue that has recently received attention from health economists is how to handle the problem of missing data in stochastic cost-effectiveness analysis. The purpose of this paper is to highlight the impact that different approaches to the imputation of missing data can have on estimates of the physical quantities of medical care resource use. METHODS: Medical care resource use data were collected prospectively in a 6-month RCT comparing two treatments for a chronic condition that is characterised by acute episodes. Two approaches of the multiple imputation were used to address the problem of missing data. Method A relied on imputing missing data for total costs and then estimating the physical quantities of medical care resource use. Method B relied on imputing missing data for the physical quantities of medical care resource use and then estimating total costs. Results for physician and nurse visits and days in the hospital were reported. RESULTS: The two multiple imputation approaches produced different estimates of medical care resource use. For method A, the average number of physician and nurse visits and days in the hospital between the two groups were 5.7 vs. 5.3 physician visits, 1.0 vs. 0.9 nurse visits, and 4.0 vs. 4.7 days in the hospital. For method B the average number of physician and nurse visits and days in the hospital between the two groups were 6.0 vs. 6.3 physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0 days in the hospital. CONCLUSIONS: Medical care resource use estimates are sensitive to the imputation approach. Method B builds prediction models specifically for the utilisation components under the imputation and results from the imputed datasets are believed to be less biased. It also provides more flexibility for analysing the cost components.
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COST-EFFECTIVENESS VS. COST-UTILITY ANALYSIS: DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE REALLY MATTER?
Tengs TO, Lin TH Health Priorities Research Group, University of California, Irvine, CA, USA
The US Public Health Service Panel on Cost-Effectiveness issued a series of recommendations designed to improve the rigor and consistency of cost-effectiveness analyses. While the Panel's individual recommendations are largely sound, they nevertheless vary in importance. That is, the violation of some recommendations will yield dramatically different cost-effectiveness estimates and resource allocation decisions than the violation of other recommendations. OBJECTIVE: The Panel has advocated the use of qualityadjusted life-years (QALYs) as the best way to evaluate outcomes in a cost-effectiveness analysis. We consider the importance of this recommendation for cancer prevention, screening, and treatment by studying the empirical relationship between cost/life-year and cost/QALY. In addition, we consider whether adjusting for healthrelated quality of life (QOL) affects the ultimate resource allocation decision implied by the cost-effectiveness ratio. METHODS: We identified 198 articles reporting two or more outcome measures for the same intervention: cost/life-year, cost/QALY, total life-years, total QALYs, incremental life-years, or incremental QALYs. We calculated a correlation matrix for these outcomes and performed a regression analysis to examine the relationship between cost/life-year and cost/QALY. We also employed various willingness to pay (WTP) thresholds to assess whether the use of cost/life-year would yield different resource allocation decisions than cost/QALY. RESULTS: The correlation between the total life-years and total QALYs associated with the intervention is 0.97 (P < 0.0001). The correlation between cost/life-year and cost/QALY is 0.78 (P < 0.0001). Assuming a $50,000 WTP threshold, adjustment for QOL would affect choice in 7% of cases. With a $400,000 threshold, QOL would affect choice in 2% of cases. CONCLUSION: The outcome measures of life-years and QALYs are highly correlated with one another. While adjusting for QOL can make an important difference in some economic analyses, it generally does not affect implied resource allocation decisions for cancer prevention, screening, and treatment.
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IMPORTANCE OF CONSIDERING SENSITIVITY AND SPECIFICITY OF SCREENING METHODS IN HEALTH ECONOMIC ANALYSES OF DIABETIC NEPHROPATHY SCREENING POLICIES
Palmer AJ, Roze S CORE Center for Outcomes Research, Basel, BS, Switzerland
